1.8
薬物 - 受容体相互作用は、薬物による受容体の結合を説明しますが、すべての薬物 - 受容体相互作用が活性化と組織応答を引き起こすわけではありません。たとえば、アゴニストの結合は受容体を活性化して細胞反応を生成しますが、拮抗物質は受容体に結合しても活性化を引き起こしません。
薬物の受容体への親和性やそ…
薬物は、コンフォメーション変化を誘発したり、エフェクター分子を動員して細胞応答を生成したりすることで、その受容体を活性化します。しかし、すべての薬剤が結合時に標的や受容体を活性化するわけではありません。
薬物の結合は、受容体に対する薬物の親和性に依存します。低濃度でも、高親和性薬物は内因性リガンドと競合し、受容体の最大占有率をめぐって
争います。薬物の有効性は、細胞応答を誘発する能力を決定します。薬物は、その親和性と有効性に基づいて、アゴニスト、パーシャルアゴニスト、またはアンタゴニストに分類されます。
アゴニストは受容体を活性化して最大の反応を誘発します。アゴニストは、内因性リガンド結合部位または別のアロステリック部位に結合して、受容体の活性を高めることができます。受容体が全占有されていなくても、アゴニストの有効性はほぼ100%のままです。
パーシャルアゴニストは中程度の有効性を持ち、受容体占有率が100%であっても最大以下の反応しか出せません。.
最後に、アンタゴニストは内因性リガンドと競合して、受容体に結合して不活性化します。したがって、拮抗薬の有効性はごくわずかであり、反応を生じさせません。
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between drug affinity and drug efficacy?
Drug affinity is the ability of a drug to bind to its receptor, determining how readily it occupies receptor sites even at low concentrations. Efficacy is the drug's ability to activate the receptor and elicit a cellular response. High-affinity drugs compete effectively with endogenous ligands for receptor occupancy, while efficacy determines whether that binding produces a maximal, submaximal, or negligible response.
Q2: How do agonists activate receptors to produce a cellular response?
Agonists activate receptors by inducing conformational changes or recruiting effector molecules that generate a cellular response. They can bind to the endogenous ligand binding site or a separate allosteric site to increase receptor activity. Agonists have high affinity and nearly 100% efficacy, producing maximal responses even without total receptor occupancy.
Q3: Why do partial agonists produce submaximal responses despite full receptor occupancy?
Partial agonists have intermediate efficacy, meaning they cannot fully activate receptors even when bound to all available receptor sites. Unlike agonists with nearly 100% efficacy, partial agonists are intrinsically limited in their ability to generate a cellular response. This reduced efficacy results in submaximal tissue responses regardless of complete receptor occupancy.
Q4: What mechanism allows antagonists to block drug responses?
Antagonists compete with endogenous ligands and agonists for receptor binding sites, stabilizing the receptor in an inactive state. They have negligible efficacy and do not produce a response themselves. By occupying receptors, antagonists prevent agonists from binding and activating the receptor, effectively blocking the cellular response.
Q5: How do allosteric antagonists differ from pharmacologic antagonists?
Pharmacologic antagonists compete directly with other molecules for the same receptor binding site and stabilize the receptor in an inactive state. Allosteric antagonists bind to separate sites on the receptor and change the affinity and efficacy of agonists without competing for the primary binding site. Both reduce receptor activation but through distinct mechanisms.
Q6: Why is understanding drug-receptor binding essential for predicting drug effects?
Drug-receptor interactions determine whether a drug activates or inactivates its target, directly influencing tissue response. The drug's affinity, efficacy, and binding mechanism—whether at the agonist site or allosteric site—collectively determine its pharmacological effect. Understanding these interactions is critical for predicting how factors affecting drug response will influence therapeutic outcomes.
Q7: What determines whether a drug will be classified as an agonist, partial agonist, or antagonist?
Drug classification depends on two parameters: affinity and efficacy. Agonists have high affinity and high efficacy, producing maximal responses. Partial agonists have high affinity but intermediate efficacy, producing submaximal responses. Antagonists have variable affinity but negligible efficacy, producing no response. These properties determine the drug's functional effect on tissue.